PRAX实时信号 | 通过Getagraph.com最大化利润

购买 107548 min ago

@ $42.09

发出时间: 15 Feb 2024 @ 03:09

回报率: 30.20%

上一信号: Feb 14 - 23:24

上一信号: 出售

回报率: -4.89 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance...

Stats
今日成交量	140 175
平均成交量	203 709
市值	936.42M
EPS	$0 ( 2024-03-05 )
下一个收益日期	( $-2.01 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.93
ATR14	$0.150 (0.27%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-12	Mastrocola Lauren	Sell	48	Common Stock
2024-02-12	Nemiroff Alex	Sell	51	Common Stock
2024-02-12	Souza Marcio	Sell	271	Common Stock
2024-01-12	Kelly Timothy Edwin	Buy	30 000	Stock Option (Right to Buy)
2024-01-12	Souza Marcio	Buy	100 000	Stock Option (Right to Buy)

INSIDER POWER
98.10
Last 99 transactions
Buy: 3 195 196 \| Sell: 875 304

音量相关性

長: -0.10 (neutral)

短: -0.03 (neutral)

Signal:(55.054) Neutral

Praxis Precision 相关性

10 最正相关
EUSG	0.899
AAWW	0.893
VICR	0.884
CVCY	0.865
CASH	0.861
BPRN	0.859
PXLW	0.848
SMSI	0.842
IMAB	0.839
CIZN	0.837

10 最负相关
MOSY	-0.87
APOP	-0.826

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Praxis Precision 相关性 - 货币/商品

-0.48
( neutral )

0.50
( neutral )

0.00
( neutral )

0.19
( neutral )

0.35
( neutral )

-0.31
( neutral )

Praxis Precision 财务报表

Annual	2023
营收:	$2.45M
毛利润:	$2.02M (82.35 %)
EPS:	$-18.69

FY	2023
营收:	$2.45M
毛利润:	$2.02M (82.35 %)
EPS:	$-18.69

FY	2022
营收:	$0
毛利润:	$-1.17M (0.00 %)
EPS:	$-69.33

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-3.74

Financial Reports:

No articles found.

Praxis Precision

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.